Artivion (NYSE:AORT) EVP Sells $238,618.48 in Stock

Artivion, Inc. (NYSE:AORT) EVP Lance Berry sold 6,316 shares of Artivion stock in a transaction on Tuesday, March 3rd. The stock was sold at an average price of $37.78, for a total value of $238,618.48. Following the sale, the executive vice president owned 210,827 shares in the company, valued at $7,965,044.06. This trade represents a 2.91% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this link.

Artivion Stock Performance

NYSE AORT traded down $0.21 on Wednesday, hitting $38.41. 460,494 shares of the stock traded hands, compared to its average volume of 509,518. The company has a debt-to-equity ratio of 0.49, a quick ratio of 2.62 and a current ratio of 3.53. The business’s fifty day moving average is $41.42 and its two-hundred day moving average is $42.92. Artivion, Inc. has a 12 month low of $21.97 and a 12 month high of $48.25. The firm has a market capitalization of $1.84 billion, a price-to-earnings ratio of 61.30 and a beta of 1.60.

Artivion (NYSE:AORT) last issued its quarterly earnings results on Thursday, February 12th. The company reported $0.17 EPS for the quarter, beating analysts’ consensus estimates of $0.14 by $0.03. Artivion had a return on equity of 7.43% and a net margin of 2.21%.The firm had revenue of $118.30 million for the quarter, compared to analysts’ expectations of $116.42 million. The business’s quarterly revenue was up 19.2% compared to the same quarter last year. As a group, equities analysts anticipate that Artivion, Inc. will post 0.37 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on AORT shares. Oppenheimer restated an “outperform” rating and set a $50.00 price target on shares of Artivion in a research note on Friday, November 7th. Needham & Company LLC reiterated a “buy” rating and set a $58.00 price objective on shares of Artivion in a research note on Monday, February 2nd. Canaccord Genuity Group cut their target price on Artivion from $51.00 to $48.00 and set a “buy” rating for the company in a research note on Friday, February 13th. Citizens Jmp upped their price target on Artivion from $47.00 to $53.00 and gave the company a “market outperform” rating in a research report on Friday, November 7th. Finally, Weiss Ratings raised shares of Artivion from a “sell (d)” rating to a “hold (c-)” rating in a report on Friday, February 20th. Six equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $48.97.

More Artivion News

Here are the key news stories impacting Artivion this week:

• Positive Sentiment: Analysts remain constructive — consensus rating is “Moderate Buy” with several buy/outperform notes and mid‑to‑high price targets that support investor demand. Artivion Receives Consensus Rating
• Positive Sentiment: Management will present at the Oppenheimer Healthcare MedTech & Services Conference (virtual fireside chat), giving the company an opportunity to update investors on growth drivers, product progress and commercial milestones. Conferences can re‑ignite buying interest if guidance or pipeline commentary is favorable. Artivion to Participate in Oppenheimer Conference
• Positive Sentiment: Large institutional investors have been adding exposure (Invesco and others increased stakes), which can provide a steady bid and signals confidence from professional investors. MarketBeat – Artivion Institutional Activity
• Neutral Sentiment: Recent quarterly results beat revenue and EPS estimates and showed strong year‑over‑year revenue growth; that supports the bull case but may already be reflected in the share price and analyst upgrades. MarketBeat – Artivion Earnings Summary
• Negative Sentiment: Multiple senior insiders sold stock over March 2–4 (including the CEO and several EVPs/SVPs). A concentrated block of insider sales often weighs on sentiment even when executives retain large holdings — markets can interpret it as opportunistic liquidity or as a signal of limited near‑term confidence. Insider Trades Alert

Institutional Trading of Artivion

Several institutional investors and hedge funds have recently modified their holdings of AORT. Royal Bank of Canada grew its position in Artivion by 107.0% in the first quarter. Royal Bank of Canada now owns 38,707 shares of the company’s stock worth $952,000 after acquiring an additional 20,010 shares in the last quarter. AQR Capital Management LLC lifted its stake in Artivion by 8.8% during the first quarter. AQR Capital Management LLC now owns 35,053 shares of the company’s stock worth $862,000 after purchasing an additional 2,823 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of Artivion by 4.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 23,591 shares of the company’s stock worth $580,000 after purchasing an additional 1,032 shares in the last quarter. Envestnet Asset Management Inc. increased its position in shares of Artivion by 364.4% during the 2nd quarter. Envestnet Asset Management Inc. now owns 52,871 shares of the company’s stock valued at $1,644,000 after purchasing an additional 41,487 shares during the last quarter. Finally, Atria Investments Inc purchased a new position in shares of Artivion during the 2nd quarter valued at about $244,000. Hedge funds and other institutional investors own 86.37% of the company’s stock.

About Artivion

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.